Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Discussing Guidance On Giving Drug Economic Data To Formulary Managers

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA official Tom Abrams recently acknowledged heightened stakeholder interest in guidance on appropriate communications of health care economic data under FDAMA Sec. 114.

Advertisement

Related Content

Rx Firms Still Bear Promotional Compliance Burden If Social Media Platform Changes, FDA Says
Health Economic Promotions To Formulary Managers: Seldom Used Or Under The Radar?

Topics

Advertisement
UsernamePublicRestriction

Register

PS075983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel